23,000 Shares in CG Oncology, Inc. $CGON Purchased by Jupiter Topco LLC

Jupiter Topco LLC purchased a new stake in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 23,000 shares of the company's stock, valued at approximately $1,634,000.

Several other large investors have also recently added to or reduced their stakes in the company. Fiduciary Financial Advisors bought a new position in CG Oncology in the second quarter worth $28,000. NFSG Corp acquired a new position in shares of CG Oncology in the 1st quarter worth approximately $34,000. Comerica Bank lifted its holdings in shares of CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company's stock valued at $43,000 after acquiring an additional 515 shares during the period. Fifth Third Bancorp bought a new stake in CG Oncology during the first quarter worth about $74,000. Finally, KBC Group NV acquired a new position in shares of CG Oncology in the 1st quarter worth approximately $78,000. Institutional investors and hedge funds own 26.56% of the company's stock.

CG Oncology Price Performance

Shares of CGON stock opened at $74.67 on Friday. The stock has a 50-day moving average of $73.63 and a 200-day moving average of $67.25. The stock has a market cap of $6.62 billion, a PE ratio of -27.76 and a beta of 0.24. CG Oncology, Inc. has a one year low of $29.85 and a one year high of $80.97.

CG Oncology (NASDAQ:CGON - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.24). CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%. The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $0.36 million. As a group, research analysts anticipate that CG Oncology, Inc. will post -3.27 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CGON. Wedbush lifted their price objective on CG Oncology from $77.00 to $80.00 and gave the company an "outperform" rating in a research report on Monday, May 11th. Royal Bank Of Canada lowered their target price on CG Oncology from $81.00 to $79.00 and set an "outperform" rating for the company in a research note on Friday, August 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of CG Oncology in a research report on Friday, July 17th. JPMorgan Chase & Co. raised their price objective on shares of CG Oncology from $91.00 to $96.00 and gave the company an "overweight" rating in a research report on Monday, May 11th. Finally, Piper Sandler boosted their target price on shares of CG Oncology from $82.00 to $85.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, CG Oncology currently has a consensus rating of "Moderate Buy" and an average target price of $83.18.

Insiders Place Their Bets

In related news, Director Brian Liu purchased 371,085 shares of CG Oncology stock in a transaction that occurred on Thursday, June 25th. The stock was purchased at an average cost of $66.87 per share, with a total value of $24,814,453.95. Following the completion of the transaction, the director owned 1,886,236 shares of the company's stock, valued at approximately $126,132,601.32. This trade represents a 24.49% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James Mulay sold 24,165 shares of the stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $75.16, for a total value of $1,816,241.40. Following the completion of the sale, the director directly owned 24,165 shares of the company's stock, valued at approximately $1,816,241.40. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 37,129 shares of company stock valued at $2,683,857 in the last three months. 4.80% of the stock is currently owned by corporate insiders.

About CG Oncology

CG Oncology, Inc NASDAQ: CGON is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source